SecBot SecBot
SECBOTREPLAY Home › Report › LGND

LGND · Director John Kozarich and CLO Andrew Reardon sold a combined $155K in…

LIGAND PHARMACEUTICALS INC · CLUSTER filed Apr 30, 2026 at 20:00 ET

At the news

NEUTRALIMPACT 3/10

CLUSTER filed Apr 30, 2026 at 20:00 ET

Director John Kozarich and CLO Andrew Reardon sold a combined $155K in open-market sales on May 1, 2026, following Ligand's strong Q1 earnings (royalty revenue +56% YoY) and the reaffirmation of raised 2026 guidance tied to the pending XOMA acquisition. The sales are small relative to the $4.4B market cap (0.0035%) and likely reflect routine portfolio rebalancing or tax planning, not a bearish signal on fundamentals.

  • Two insiders sold a total of 680 shares for $155K on May 1, 2026.
  • Sales represent ~0.0035% of Ligand's $4.4B market cap, trivial in size.
  • Director Kozarich also exercised and sold shares on May 12-13, 2026, in a separate cluster ($455K total).
  • Q1 2026 earnings showed royalty revenue up 56% YoY to $43M; adjusted EPS of $1.63 beat prior year's $1.33.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access